– USA, CA – Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of Patrick Machado to its Board of Directors.
Mr. Machado brings significant operating experience, including his time as a co-founder, chief business officer and CFO of Medivation, Inc., where he provided strong leadership in the development of XTANDI and its successful commercial launch in prostate cancer. He also served as a member of Medivation’s Board of Directors until its acquisition by Pfizer in 2016.
“With Principia having multiple mid- and late-stage clinical development programs in place, Pat’s business acumen and experience at high-growth companies is very well suited to our vision for the next several years,” said Martin Babler, president and CEO at Principia Biopharma. “Having spent more than 20 years leading finance, business development, and legal functions through every phase of growth for a commercial biopharmaceutical company, Pat brings a wealth of experience to our Board.”
About Pat Machado
Before joining Medivation, Mr. Machado worked at ProDuct Health, Inc. as senior vice president, chief financial officer, and general counsel from 1998 to 2001. Upon ProDuct Health’s acquisition by Cytyc Corporation, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Chiron Corporation as chief legal counsel and business development representative to Chiron Technologies business unit. Prior to that, he worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.
About Principia Biopharma
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency platform enables the company to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease. PRN2246/SAR442168, a covalent BTK inhibitor which crosses the blood-brain barrier, has commenced a Phase 2 clinical trial in patients with multiple sclerosis and has been partnered with Sanofi for that disease and other diseases of the central nervous system. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor is being evaluated in a Phase 1 trial in patients with bladder cancer.
For more information: https://www.principiabio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.